Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has reported promising results from its Phase IIb TACTI-003 trial, demonstrating that its immunotherapy efti, when combined with KEYTRUDA, significantly enhances response rates in treating head and neck cancer, particularly in patients with high PD-L1 expression. The combination therapy also showed a high durability of response (17.5 months) and increased biological activity without compromising safety. These findings, presented at the ESMO Congress 2024, suggest a potential new treatment avenue for patients with recurrent or metastatic head and neck squamous cell carcinoma.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
